156 related articles for article (PubMed ID: 28604479)
1. 18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer.
Venema C; de Vries E; Glaudemans A; Poppema B; Hospers G; Schröder C
Clin Nucl Med; 2017 Aug; 42(8):612-614. PubMed ID: 28604479
[TBL] [Abstract][Full Text] [Related]
2. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
6. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
[TBL] [Abstract][Full Text] [Related]
7. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
8. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
[TBL] [Abstract][Full Text] [Related]
9. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
10. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
11. Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.
Boers J; Schröder CP; Hospers GAP; de Vries EFJ; Glaudemans AWJM
Clin Nucl Med; 2021 Mar; 46(3):e165-e167. PubMed ID: 33181752
[TBL] [Abstract][Full Text] [Related]
12. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
[TBL] [Abstract][Full Text] [Related]
14. Lobular breast carcinoma: a case of rare possible 18F-FDG PET/CT and bone scan false negative.
Maffione AM; Lisato LC; Rasi A; Marzola MC; Colletti PM; Rubello D
Clin Nucl Med; 2015 Feb; 40(2):e134-6. PubMed ID: 24999681
[TBL] [Abstract][Full Text] [Related]
15. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with 18F-FDG and 18F-FES.
Hołody Ł; Kunikowska J; Braziewicz J
Nucl Med Rev Cent East Eur; 2018; 21(2):113-114. PubMed ID: 29956818
[TBL] [Abstract][Full Text] [Related]
18. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
19. Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances.
Kanne JP; Mankoff DA; Baird GS; Minoshima S; Livingston RB
AJR Am J Roentgenol; 2007 Jun; 188(6):W503-5. PubMed ID: 17515338
[No Abstract] [Full Text] [Related]
20. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
Evangelista L; Guarneri V; Conte PF
Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]